NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...
Zacks Investment Research on MSN22h
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue EstimatesBioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback